Full Text View
Tabular View
No Study Results Posted
Related Studies
Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia (ARETA)
This study is currently recruiting participants.
Verified March 2013 by AOP Orphan Pharmaceuticals AG
Study NCT01230775   Information provided by AOP Orphan Pharmaceuticals AG

First Received on October 28, 2010.   Last Updated on March 5, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Essential Thrombocythaemia
Additional conditions recognized in this trial
Thrombocythemia, Essential
Thrombocytosis
More general conditions related to this trial
Blood Coagulation Disorders
Blood Platelet Disorders
Bone Marrow Diseases
Hematologic Diseases
Hemorrhagic Disorders
Myeloproliferative Disorders
Interventions listed in this trial
Anagrelide retard
Placebo
Additional drug interventions recognized in this trial
Anagrelide
More general drug interventions related to this trial
Cardiovascular Agents
Fibrin Modulating Agents
Fibrinolytic Agents
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Platelet Aggregation Inhibitors
Therapeutic Uses
Sponsors listed in this trial
AOP Orphan Pharmaceuticals AG


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services